


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I)



in which:

R<sup>1</sup> represents H or CH<sub>3</sub>;


R<sup>2</sup> represents H, halogen, cyano, C1 to 2 alkyl, trifluoromethyl or C1 to 2 alkoxy;

n represents an integer 1, 2 or 3;

m represents an integer 0, 1, 2 or 3;


R<sup>3</sup> represents H, C2 to 4 alkenyl or C1 to 4 alkyl; said alkyl group being optionally further substituted by CN, C1 to 4 alkoxy, C1 to 4 alkyl-SO<sub>2</sub>- or one or more fluoro atoms;

or R<sup>3</sup> represents a C1 to 4 alkylene group that forms a 4 to 7 membered azacyclic ring by virtue of being additionally bonded to either the aromatic ring, Ar, or to the linker group,



$\text{R}^4$  and  $\text{R}^5$  independently represent H or C1 to 2 alkyl; or the group  $\text{CR}^4\text{R}^5$  together represents a 3 to 6 membered carbocyclic ring that optionally incorporates one heteroatom selected from O or S; and each  $\text{R}^4$ , each  $\text{R}^5$  and each group  $\text{CR}^4\text{R}^5$  is selected independently;

Ar represents a phenyl ring or a 5- or 6-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S; said phenyl or heteroaromatic ring being optionally substituted by one or more substituents selected independently from halogen, cyano, C1 to 2 alkyl, trifluoromethyl, C1 to 2 alkoxy,  $\text{NR}^6\text{R}^7$ ,  $-\text{CONR}^6\text{R}^7$ ,



$\text{R}^6$  and  $\text{R}^7$  independently represent H, C2 to 4 alkenyl or C1 to 4 alkyl; said alkyl or alkenyl groups being optionally further substituted by one or more halogen atoms;

p represents an integer 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

2. (Original) A compound of formula (I), according to Claim 1, wherein n represents the integer 1.

3. (Currently amended) A compound of formula (I), according to Claim 1 ~~or Claim 2~~, wherein  $\text{R}^1$  represents H.


4. (Currently amended) A compound of formula (I), according to ~~any one of Claims 1 to 3~~ Claim 1, in which Ar represents optionally substituted phenyl or optionally substituted pyridyl.

5. (Currently amended) A compound of formula (I), according to ~~any one of Claims 1 to 4~~ Claim 1, in which each  $\text{R}^4$  and each  $\text{R}^5$  represents H.

6. (Currently amended) A compound of formula (I), according to ~~any one of Claims 1 to 5~~ Claim 1, in which m represents the integer 1.


7. (Currently amended) A process for the preparation of a compound of formula (I), according to ~~any one of Claims 1 to 6~~ Claim 1, which comprises:

(a) reaction of a compound of formula (II):




wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , Ar, m and n are as defined in Claim 1, with an isocyanate; or

(b) reaction of a compound of formula (III)




wherein  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^5$  and  $n$  are as defined in Claim 1 and LG represents a leaving group, with an amine ( $R^3NH(CR^4R^5)_m-Ar$ ) wherein  $R^3$ ,  $R^4$ ,  $R^5$ ,  $Ar$  and  $m$  are as defined in Claim 1; or

(c) reaction of a compound of formula (IV)




wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $m$ ,  $n$  and  $Ar$  are as defined in Claim 1, with a compound of formula (V)




wherein  $R^1$  is as defined in Claim 1 and LG represents a leaving group; or

(d) reaction of a compound of formula (VI)



wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $m$ ,  $n$  and Ar are as defined in Claim 1 and LG represents a leaving group,

with a compound of formula (VII)



wherein R<sup>1</sup> is as defined in Claim 1;

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

8. (Currently amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in ~~any one of claims 1 to 6~~ Claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

9. (Currently amended) A pharmaceutical composition adapted for administration by inhalation or insufflation ~~[[.]]~~ comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in ~~any one of claims 1 to 6~~ Claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

10. (Currently amended) A process for the preparation of a pharmaceutical composition ~~as claimed in Claim 8~~ which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in ~~any one of claims 1 to 6~~ Claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. (Cancelled)

12. (Cancelled)

13. (Currently amended) A method or the treatment or prophylaxis of inflammatory disease comprising administering to a person suffering from or at risk of said inflammatory disease a therapeutically effective amount of ~~Use of~~ a compound of formula (I), or a

pharmaceutically acceptable salt thereof, as claimed in ~~any one of claims 1 to 6~~ Claim 1, ~~in the manufacture of a medicament for use in the treatment or prophylaxis of inflammatory disease.~~

14. (Currently amended) The ~~[[use]]~~ method as claimed in Claim 13 wherein the disease is rheumatoid arthritis.

15. (Currently amended) The ~~[[use]]~~ method as claimed in Claim 13 wherein the disease is chronic obstructive pulmonary disease.

16. (Cancelled)

17. (Currently amended) A method of treating, or reducing the risk of, ~~diseases or conditions~~ a disease or a condition in which inhibition of IKK-2 activity is beneficial which comprises administering to a person suffering from or at risk of said disease or condition a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in ~~any one of claims 1 to 6~~ Claim 1.

18. (New) The method as claimed in Claim 17, wherein the disease is cancer.